Cardiome Pharma announces $30 mln primary and secondary offering
Cardiome Pharma Corp (NASDAQ: CRME, TSX: COM) and CarCor Investment Holdings LLC, the shareholder from which Cardiome bought Swiss pharmaceutical company Correvio LLC in late 2013, have agreed to primary and secondary offerings totaling $30 million. Cardiome will use the proceeds of the primary offering for working capital and general corporate purposes, including to fund expansion of sales and marketing efforts. Around the time of the Correvio acquisition, Cardiome is reported to have received an investment from U.S. private equity firm Fortress Investment Group. Based in Vancouver, the company is focused on the development and commercialization of cardiovascular therapies.
24 February 2014•5 mins read
